Sentimag - Magseed in breast cancer

In recent years, advancements in medical practices have offered more women diagnosed with breast cancer the opportunity to receive breast-conserving and lymph node-sparing surgery. At any stage, the target is to de-escalate the surgical radicality.

To ensure both oncologic safety and patient comfort, reliable marking of lesions and target lymph nodes is a prerequisite. However, many tissue markers encounter significant challenges, including:

• unreliable detectability due to migration or low visibility in imaging
• radiation exposure
• not always suitable for long-term placement
• not always suitable for each tissue type

As a result, patients can experience discomfort, such as unnecessary anxiety, physical pain and a suboptimal cosmetic outcome.

The Magseed^® marker has been specifically designed to overcome the challenges of other clip, reflector, tag, radioseed and wire markers. It enables a flexible patient treatment pathway – from placement of the marker until the day of surgery. Magseed^® promotes high oncologic safety, accurate tissue localisations and improved patient satisfaction, preventing unnecessary surgery and helping to reduce the extent of the required ones.

Magseed^® is used alongside the Sentimag^® system, a sensitive magnetic detector that locates the seed. The marker is deployed under ultrasound or X-ray guidance any time before surgery. Once in the operating room, the surgeon then uses the Sentimag^® system’s probe to precisely locate the Magseed^®, and thereby the lesion or lymph node in which the Magseed^® has been placed.

Endomag^®, Sentimag^® and Magseed^® are registered European Union trademarks of Endomagnetics Ltd www.endomag.com

Magtrace^® is a registered trademark of Endomagnetics Ltd in the United Kingdom www.endomag.com